While Supernus Pharmaceuticals Inc has overperformed by 1.50%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SUPN rose by 19.80%, with highs and lows ranging from $43.73 to $29.16, whereas the simple moving average jumped by 24.79% in the last 200 days.
On July 30, 2025, Cantor Fitzgerald Upgraded Supernus Pharmaceuticals Inc (NASDAQ: SUPN) to Overweight. A report published by Cantor Fitzgerald on February 19, 2025, Downgraded its rating to ‘Neutral’ for SUPN. Cantor Fitzgerald also rated SUPN shares as ‘Overweight’, setting a target price of $57 on the company’s shares in an initiating report dated January 06, 2025. Piper Sandler September 11, 2024d the rating to Neutral on September 11, 2024, and set its price target from $41 to $36. Jefferies initiated its ‘Buy’ rating for SUPN, as published in its report on January 03, 2023. Jefferies’s report from December 01, 2021 suggests a price prediction of $44 for SUPN shares, giving the stock a ‘Buy’ rating. Jefferies also rated the stock as ‘Buy’.
Analysis of Supernus Pharmaceuticals Inc (SUPN)
Further, the quarter-over-quarter decrease in sales is -1.71%, showing a negative trend in the upcoming months.
Supernus Pharmaceuticals Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of 6.38% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.43, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and SUPN has an average volume of 781.69K. On a monthly basis, the volatility of the stock is set at 4.11%, whereas on a weekly basis, it is put at 2.83%, with a gain of 2.73% over the past seven days. Furthermore, long-term investors anticipate a median target price of $43.00, showing decline from the present price of $43.32, which can serve as yet another indication of whether SUPN is worth investing in or should be passed over.
How Do You Analyze Supernus Pharmaceuticals Inc Shares?
Drug Manufacturers – Specialty & Generic giant Supernus Pharmaceuticals Inc (SUPN) is based in the USA and is one of the largest companies in the market. When comparing Supernus Pharmaceuticals Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 37.86, there is a growth in quarterly earnings of 11.14%.
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 5.66%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 106.06% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
